---
title: "Publications"
permalink: /publications/
layout: single
---

Here are some selected publications from my research work.

---

## 2025

### ![Alt text](/assets/images/DMS_model.jpg){: width="300px" style="float: left; margin-right: 15px;" }
**SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity**  

Authors: **Cooper G.W.**, Lee B.P., Kim W.J., Su Y., Chen V.Z., Salas E. Yang X., Lintner R.E., Piccioni F., Giacomelli A.O., Howard T.P., Bagchi P., Conneely K.N., Root D.E., Liang B., Hahn W.C., Gorkin D.U., Biegel J.A., Chi S.N., Hong A.L.  
Journal: Nature Communications* (Under review)  
Summary: Mapped 8,418 SMARCB1 missense mutations, revealing for the first time that specific missense mutants disrupt protein flexibility and abolish functionâ€”advancing molecular diagnostics in 
SMARCB1-related cancers.

[<span style="color:#1a73e8;">Read more</span>](https://doi.org/10.21203/rs.3.rs-6018128/v1)  


---

## 2024

### ![Alt text](/assets/images/TRIP13.jpg){: width="300px" style="float: left; margin-right: 15px;" }
**Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin**

Authors: * Mittal K., *** Cooper G.W.**, * Lee B.P.,Su Y., Skinner K.T., Shim J., Jonus H.C., Kim W.J., Doshi M., Almanza D., Kynnap B.D., Christie A.L., Yang X., Cowley G.S., Leeper B.A., Morton C.L., Dwivedi B., Lawrence T., Rupji M., Keskula P., Meyer S., Clinton C.M., Bhasin M., Crompton B.D., Hong A.L.  
Journal: *Communications Biology*  
Summary: Identified nuclear export inhibition as a therapeutic vulnerability in Wilms tumor, acting through TRIP13 suppression. Demonstrated synergy with doxorubicin, resulting in curative responses 
in preclinical models.

[<span style="color:#1a73e8;">Read more</span>](https://doi.org/10.1038/s42003-024-06140-6)  


___

## 2022

### ![Alt text](/assets/images/SMARCB1_review.jpg){: width="400px" style="float: left; margin-right: 30px;" }
**SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities**

Authors: **Cooper G.W.**, Hong H.L.

Journal: *Cancers*

Summary: SMARCB1 loss drives several aggressive cancers with limited treatment options. This review highlights recent insights into its function and emerging therapeutic vulnerabilities.

[<span style="color:#1a73e8;">Read more</span>](https://doi.org/10.3390/cancers14153645)

